Fig. 6: Safety evaluation of 3C-LNPs.
From: Gene Therapy with Enterovirus 3 C Protease: A Promising Strategy for Various Solid Tumors
a–d BALB/c female nude mice were intracranially administered 1.2 μg of 3C-LNPs twice per week for 3 weeks. b and c Body weight and survival curves of mice intracranially administered 3C-LNPs (n = 6 mice/group). d Histopathological examination of major organs collected after the animals were administered PBS or 3C-LNPs (n = 6 mice/group). Scale bar: 100 µm. e–j BALB/c mice were intravenously administered with 0.43 mg/kg or 0.65 mg/kg 3C-LNPs once a week for six weeks. f, g Body weight and survival curves of BALB/c mice (n = 6 mice/group). Liver function (h) (aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP)) and total blood cell counts. The data are presented as the means ± SEMs. Statistical differences were assessed using one-way ANOVA with the Dunnett multiple comparisons test. i were evaluated 4 weeks after six weeks of treatment (n = 3 mice/group). The data are presented as the means ± SEMs. Statistical differences were assessed using Multiple t-test with the Dunnett multiple comparisons test. n.s.=not significant. Source data are provided as a Source Data file.
